Immunic, inc. announces that oral treatment imu-838 shows evidence of clinical activity in moderate covid-19 in phase 2 calvid-1 trial

New york, feb. 17, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that its lead asset, imu-838, the...
IMUX Ratings Summary
IMUX Quant Ranking